May 27, 2021
May 27, 2021 – The U.S. FDA has approved a new indication for Zeposia® (ozanimod), manufactured by
Bristol Myers Squibb, to treat adults who have moderately to severely
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
News
May 27, 2021
May 27, 2021 – The U.S. FDA has approved a new indication for Nurtec® ODT (rimegepant), manufactured
by Biohaven, for the preventive treatment of episodic migraines
May 26, 2021
May 26, 2021 – The U.S. FDA has granted emergency use authorization (EUA) to GlaxoSmithKline’s
May 26, 2021
May 26, 2021 – The U.S. FDA has issued a safety communication regarding the use of Ocaliva® (obeticholic
acid), manufactured by Intercept Pharmaceuticals, in certain patients who have
May 26, 2021
May 26, 2021 – The U.S. FDA has approved Myfembree® (relugolix 40mg/estradiol 1mg/norethindrone
acetate 0.5mg), manufactured by Myovant and Pfizer
May 26, 2021
May 26, 2021 – The U.S. FDA has approved Camcevi® (leuprolide mesylate), manufactured by Foresee
Pharmaceuticals, to treat advanced prostate cancer in adults.
May 21, 2021
May 21, 2021 – The U.S. FDA has granted accelerated approval for RybrevantTM (amivantamab-vmjw),
manufactured by Janssen, to treat adults who have locally advanced
May 20, 2021
May 20, 2021 – The U.S. FDA has expanded emergency use authorization (EUA) for the Pfizer/BioNTech
COVID-19 vaccine to include prevention of COVID-19 in individuals 12-15 years of age